Developing Rapid-Acting Treatments for Neuropsychiatric Diseases

See latest data
Our Focus

TSND-201
a rapid-acting neuroplastogen
for PTSD

We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. 
Learn More
News

The Latest From Transcend

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone) Read More
Press Release

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)
TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)
TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)
TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89) Read More
Poster Presentation

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)
Learn More
Our Mission

Striving for a world without neuropsychiatric disease.

Because 1 billion patients
deserve better.
Careers

Help us bring new mental health solutions to patients

Join us in creating a world free from neuropsychiatric disease.
Learn More